The latest biotech news

News and Trends 15 May 2023

New menopause drug gets FDA approval

The U.S. Food and Drug Administration has approved Astellas Pharma’s Veozah (fezolinetant), an oral medication for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause. Astellas Pharma US, Inc.’s Veozah is the first neurokinin 3 (NK3) receptor antagonist approved by the FDA to treat moderate to severe hot flashes from […]

May 15, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 15 May 2023

Alzheimer’s drugs could result from immune brain cell discovery

A recent study published in Nature Neuroscience indicates that, contrary to common belief, the immune cells of the brain, known as microglia, are not all the same. Researchers found that a unique microglial subset with unique features and function is important for establishing proper cognitive functions in mice. Evidence for such microglial subsets exists also […]

May 15, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 12 May 2023

DiogenX raises €27.5M for “breakthrough” diabetes treatment

DiogenX, a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes, has announced the successful completion of a €27.5 million ($30 million) Series A financing round. New investors Roche Venture Fund, Eli Lilly and Company and Omnes joined this round alongside existing investors Boehringer Ingelheim Venture Fund (BIVF), JDRF T1D Fund, […]

May 12, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 12 May 2023

Achilles Therapeutics’ new platform identifies most potent T-cell antigens

Achilles Therapeutics plc says its newly-developed AI application, trained with proprietary real-world data, outperformed current AI and non-AI methods for neoantigen immunogenicity prediction in a recent analysis, enabling the identification of the most potent clonal neoantigens for personalized cancer therapies. Further details of the company’s AI-powered PELEUS bioinformatics platform are expected to be presented at […]

May 12, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 12 May 2023

Cell and gene therapy company NewBiologix exits stealth with $50M

NewBiologix SA has emerged from stealth as a technology innovation company developing a proprietary and breakthrough platform for the advanced engineering of cell lines used to manufacture gene and cell therapies. The company’s DNA-based platform is being developed to address key manufacturing challenges associated with the production of recombinant adeno-associated virus (rAAV) vectors used to […]

May 12, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 12 May 2023

5 highlights at first Genomics and Precision Medicine Expo

Genomics and Precision Medicine Expo – taking place on May 23 and 24 2023 at ExCeL London – has announced its top 5 highlights for this year’s inaugural conference. The event, which is being run in partnership with Genomics England, will explore the latest advancements and developments in genome sequencing and genomic testing, and the […]

May 12, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 10 May 2023

Scientists create first CRISPR-based drug candidate targeting the microbiome

A new CRISPR-based drug candidate targeting E. coli in the gut microbiome is in phase 1 clinical trials. According to a new paper published in Nature Biotechnology, it may improve the well-being of blood cancer patients and reduce their mortality rate from E. coli infections. Many people have experienced infections from E. coli, which are […]

May 10, 2023 - 6 minutesmins - By Jim Cornall

News and Trends 10 May 2023

Delivering on the need for vector innovation in genetic medicine

By Tuyen Ong, CEO Ring Therapeutics, CEO-Partner Flagship Pioneering Gene therapy is a life-changing class of medicine that can treat patients with once intractable diseases. While revolutionary, significant limitations remain for the vectors that carry them. Viruses are masters at delivering genetic material to the nucleus of the organisms they infect, and because of this, […]

May 10, 2023 - 2 minutesmins - By External Contributor

News and Trends 10 May 2023

Cell rejuvenation for age-related diseases

By Sharon Rosenzweig-Lipson, CSO, Life Biosciences Cellular rejuvenation is quickly becoming a hot topic in the development of novel therapeutic modalities for a range of diseases. The leading approaches to cellular rejuvenation currently in development utilize epigenetic reprogramming to achieve this goal. Epigenetics is the study of how positive and negative lifestyle factors (exercise, smoking, […]

May 10, 2023 - 3 minutesmins - By External Contributor

News and Trends 9 May 2023

Gilead boosts oncology pipeline with XinThera acquisition

Gilead Sciences, Inc. has announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego. Gilead Sciences said the acquisition complements its existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation. Through the acquisition, Gilead Sciences gains the rights to a portfolio […]

May 9, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 9 May 2023

Gene & cell therapy manufacturer Ascend launches with more than $130M

Ascend Gene & Cell Therapies (Ascend), a company innovating manufacturing processes to improve quality, potency, safety and cost enabling better reach for gene therapy technologies, has launched as a facilitator for gene therapy companies to help translate product ideas into clinical programs. Ascend Gene & Cell Therapies offers process development, clinical manufacturing, and analytical and […]

May 9, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 9 May 2023

Ultra-long protein fibrils could help with early Alzheimer’s diagnosis

The early diagnosis and treatment of dementia such as Alzheimer’s disease is still a big challenge. It is already known that certain proteins in the cerebrospinal fluid can be used to diagnose Alzheimer’s disease. However, the current detection methods for such biomarkers by means of biochemical tests can only confirm and quantify the presence of […]

May 9, 2023 - 3 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

New menopause drug gets FDA approval

Alzheimer’s drugs could result from immune brain cell discovery

DiogenX raises €27.5M for “breakthrough” diabetes treatment

Achilles Therapeutics’ new platform identifies most potent T-cell antigens

Cell and gene therapy company NewBiologix exits stealth with $50M

5 highlights at first Genomics and Precision Medicine Expo

Scientists create first CRISPR-based drug candidate targeting the microbiome

Delivering on the need for vector innovation in genetic medicine

Cell rejuvenation for age-related diseases

Gilead boosts oncology pipeline with XinThera acquisition

Gene & cell therapy manufacturer Ascend launches with more than $130M

Ultra-long protein fibrils could help with early Alzheimer’s diagnosis

Subscribe to our newsletter to get the latest biotech news!